BioDelivery Sciences International completed the refinancing of its existing debt agreement with a new facility from BioPharma Credit consisting of a $60 million term loan.
Amicus Therapeutics signed an agreement to obtain worldwide development and commercial rights for 10 gene therapy programs. BioPharma Credit provided a $150 million term loan to support the purchase.
Novocure entered into a $150 million term loan agreement with BioPharma Credit, an investment fund managed by Pharmakon Advisors.
TESARO, an oncology-focused biopharmaceutical company, entered into a definitive term loan agreement with Biopharma Credit and BioPharma Credit Investments IV, investment funds managed by Pharmakon Advisors.